MAPK pathway activation in pilocytic astrocytoma

• Verfasst von: Jones, David T. W. [VerfasserIn]
• Verfasst von: Witt, Olaf [VerfasserIn]
• Verfasst von: Pfister, Stefan [VerfasserIn]
• Titel: MAPK pathway activation in pilocytic astrocytoma
• Verf.angabe: David T.W. Jones, Jan Gronych, Peter Lichter, Olaf Witt, Stefan M. Pfister
• Jahr: 2012
• Jahr des Originals: 2011
• Umfang: 13 S.
• Fussnoten: Published online: 13 December 2011 ; Gesehen am 20.08.2018 ; Published online: 13 December 2011
• Titel Quelle: Enthalten in: Cellular and molecular life sciences
• Ort Quelle: Cham (ZG) : Springer International Publishing AG, 1997
• Jahr Quelle: 2012
• Band/Heft Quelle: 69(2012), 11, Seite 1799-1811
• ISSN Quelle: 1420-9071
• DOI: doi:10.1007/s00018-011-0898-9
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Astrocytoma
• Sach-SW: BRAF
• Sach-SW: Fusion
• Sach-SW: LGG
• Sach-SW: Low grade glioma
• Sach-SW: MAPK
• Sach-SW: Pilocytic
• Sach-SW: Senescence
• K10plus-PPN: 1580218547

Abstract

Pilocytic astrocytoma (PA) is the most common tumor of the pediatric central nervous system (CNS). A body of research over recent years has demonstrated a key role for mitogen-activated protein kinase (MAPK) pathway signaling in the development and behavior of PAs. Several mechanisms lead to activation of this pathway in PA, mostly in a mutually exclusive manner, with constitutive BRAF kinase activation subsequent to gene fusion being the most frequent. The high specificity of this fusion to PA when compared with other CNS tumors has diagnostic utility. In addition, the frequency of alteration of this key pathway provides an opportunity for molecularly targeted therapy in this tumor. Here, we review the current knowledge on mechanisms of MAPK activation in PA and some of the downstream consequences of this activation, which are now starting to be elucidated both in vitro and in vivo, as well as clinical considerations and possible future directions.